Natco Pharma
May 09, 2012 at 16:10 | Source: Moneycontrol.com
May 04, 2012 at 13:45 | Source: CNBC-TV18
May 04, 2012 at 13:01 | Source: CNBC-TV18
Apr 28, 2012 at 14:35 | Source: Moneycontrol.com
Apr 27, 2012 at 19:01 | Source: CNBC-TV18
Apr 02, 2012 at 09:46 | Source: Reuters
News across the web »
May 22, 2012 at 10:02 | Source: DNA India
May 22, 2012 at 10:02 | Source: DNA India
May 21, 2012 at 13:38 | Source: FirstPost
May 19, 2012 at 05:31 | Source: Economic Times
May 19, 2012 at 02:01 | Source: Business Standard
Interact & exchange stock tips & market info »
Related News »
The message in the compulsory licence granted to Natco Pharma to sell a generic version of patented cancer drug Nexavar appears to have hit home. Earlier this month, Cipla, which was already selling generic Nexavar at Rs28,000 for a month’s course ...
May 22, 2012 at 03:57 | Source: Daily News and Analysis
Bayer, of course, is fighting back: in its 37-page appeal to the Intellectual Property Appellate Board, Bayer has "demanded the withdrawal of the country’s first compulsory license given to Natco Pharma, arguing that a three-fourths reduction ...
May 24, 2012 at 02:57 | Source: Tech Dirt
In the matter of Natco Pharma Limited (Natco) and Bayer Corporation (Bayer), Natco applied for and was granted a compulsory license under Section 84(i) of the Patents Act, 1970. Under the patent law in India, a compulsory license is an involuntary contract ...
May 25, 2012 at 09:44 | Source: Mondaq
Indian pharma stocks have opened the day on a mixed note with Natco Pharma and Aurobindo Pharma trading firm. However, Indoco Remedies and J B Chemicals are facing selling pressure. As per a leading financial daily, Indian drug manufacturer Lupin Ltd is ...
May 24, 2012 at 14:53 | Source: MSN India
INTERNATIONAL drug-makers and many western governments have in recent weeks expressed concerns over the government’s move to issue the first ‘compulsory licence’ to Hyderabad-based Natco Pharma to manufacture a low-cost version of ...
May 14, 2012 at 02:48 | Source: DAWN Group
On March 9, 2012, the Indian generic pharmaceutical industry got a shot in the arm when Indian Patent Office, by invoking the compulsory license (CL) provisions of the Patents Act, allowed NATCO PHARMA LTD, an Indian generic drug manufacturer to ...
May 15, 2012 at 04:34 | Source: Mondaq
Mumbai: Prices of cancer medicines are dropping dramatically after India allowed Hyderabad’s Natco Pharma Ltd to sell a copy of German firm Bayer AG’s patented cancer drug Nexavar under compulsory licensing norms. Natco has started selling its copy of ...
May 8, 2012 at 18:04 | Source: Livemint.com
Then, the government stepped in and awarded a 'compulsory licence' to Hyderabad-based pharma company Natco, which started making it for a bargain-basement price of Rs 8,800. Cipla, which had been selling the same drug for Rs 28,000, decided to ...
May 15, 2012 at 07:19 | Source: rediff.com
(Reuters) - Drugmaker Bayer said on Saturday it had challenged an Indian patents office order that allowed domestic rival Natco Pharma to sell a cheap generic version of the German firm's liver and kidney cancer drug Nexavar in India. In March, the patents ...
May 4, 2012 at 23:59 | Source: in.news.yahoo.com
In March, India stripped Germany's Bayer of its exclusive rights to sell Nexavar, granting another Indian company, Natco Pharma , a licence to sell the generic drug at 8,880 rupees for a monthly dose, over Bayer's objections. That decision was seen as ...
May 17, 2012 at 04:31 | Source: in.news.yahoo.com